Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China.
Excellent balance sheet average dividend payer.
Share Price & News
How has Hualan Biological Engineering's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 002007's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 002007 exceeded the CN Biotechs industry which returned 73.3% over the past year.
Return vs Market: 002007 exceeded the CN Market which returned 14.8% over the past year.
Price Volatility Vs. Market
How volatile is Hualan Biological Engineering's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hualan Biological Engineering undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 002007 (CN¥41.3) is trading above our estimate of fair value (CN¥25.73)
Significantly Below Fair Value: 002007 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002007 is good value based on its PE Ratio (59.3x) compared to the Biotechs industry average (69.1x).
PE vs Market: 002007 is poor value based on its PE Ratio (59.3x) compared to the CN market (37.6x).
Price to Earnings Growth Ratio
PEG Ratio: 002007 is poor value based on its PEG Ratio (3.5x)
Price to Book Ratio
PB vs Industry: 002007 is overvalued based on its PB Ratio (11.1x) compared to the CN Biotechs industry average (6.4x).
How is Hualan Biological Engineering forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002007's forecast earnings growth (16.7% per year) is above the savings rate (3.3%).
Earnings vs Market: 002007's earnings (16.7% per year) are forecast to grow slower than the CN market (23.2% per year).
High Growth Earnings: 002007's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002007's revenue (16.5% per year) is forecast to grow slower than the CN market (16.6% per year).
High Growth Revenue: 002007's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002007's Return on Equity is forecast to be high in 3 years time (21.2%)
How has Hualan Biological Engineering performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002007 has high quality earnings.
Growing Profit Margin: 002007's current net profit margins (34.5%) are lower than last year (35.6%).
Past Earnings Growth Analysis
Earnings Trend: 002007's earnings have grown by 18.4% per year over the past 5 years.
Accelerating Growth: 002007's earnings growth over the past year (6.7%) is below its 5-year average (18.4% per year).
Earnings vs Industry: 002007 earnings growth over the past year (6.7%) exceeded the Biotechs industry -2.9%.
Return on Equity
High ROE: 002007's Return on Equity (19.1%) is considered low.
How is Hualan Biological Engineering's financial position?
Financial Position Analysis
Short Term Liabilities: 002007's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥661.3M).
Long Term Liabilities: 002007's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥4.8M).
Debt to Equity History and Analysis
Debt Level: 002007's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 002007's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 002007's debt is well covered by operating cash flow (2541.1%).
Interest Coverage: 002007 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Hualan Biological Engineering's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002007's dividend (0.75%) is higher than the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 002007's dividend (0.75%) is low compared to the top 25% of dividend payers in the CN market (1.9%).
Stability and Growth of Payments
Stable Dividend: 002007's dividend payments have been volatile in the past 10 years.
Growing Dividend: 002007's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.2%), 002007's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 002007's dividends in 3 years are forecast to be well covered by earnings (42.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Mr. Kang An serves as the Chairman of the Board of Directors of Hualan Biological Engineering Inc. and has been its General Manager since April 24, 2013.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hualan Biological Engineering Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Hualan Biological Engineering Inc.
- Ticker: 2007
- Exchange: SZSE
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥75.346b
- Shares outstanding: 1.82b
- Website: https://www.hualanbio.com
Number of Employees
- Hualan Biological Engineering Inc.
- Jia No. 1, Hualan Avenue
- Henan Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|2007||SZSE (Shenzhen Stock Exchange)||Yes||Domestic Shares||CN||CNY||Jun 2004|
|2007||XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)||Yes||Domestic Shares||CN||CNY||Jun 2004|
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China. Its plasma products comprise surgical lyophilized fibrin sealant, human coagulation factor VIII, human albumin, human fibrinogen, human hepatitis B immunoglobulin, human tetanus immunoglobulin, human prothrombin complex, human immunoglobulin, human thrombin lyophilized for external use, human rabies immunoglobulin, and human immunoglobulin (PH4) for intravenous injection. The company’s vaccines consist of meningococcal polysaccharide vaccine, inactivated influenza vaccine, recombinant hepatitis B vaccine, influenza A vaccine, and H7N9 inactivated influenza vaccine. It also offers gene products. Hualan Biological Engineering Inc. has strategic alliance with the Chinese Academy of Sciences. The company was founded in 1992 and is based in Xinxiang, the People’s Republic of China.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 14:34|
|End of Day Share Price||2020/06/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.